Continuous Infusion of Dexmedetomidine Improves Renal Ischemia-reperfusion Injury in Rat Kidney

Dexmedetomidine on renal ischemia-reperfusion injury in rats: assessment by means of NGAL and histology

“…We started with a low dose of 3 mg/kg/h but there are reports of up to 20 mg/kg/h in rats. 27 Albeit we did not have the expected results in nephroprotection with Dexmedetomidine, it is important to report those negative results in the literature, preventing selection bias on future studies and reviews. 28,29…”

Dexmedetomidine reduces the neuronal apoptosis related to cardiopulmonary bypass by inhibiting activation of the JAK2–STAT3 pathway

“… 9 A previous report observed that treatment with 5 μg/kg/h dexmedetomidine can alleviate cerebral damage in diabetic rats, 9 while treatment with 10 or 20 μg/kg/h dexmedetomidine has also been shown to reduce renal dysfunction. 27 According to dose-conversion coefficients following different animal conversions, 28 rat dosages of 2.5 μg/kg/h and 5 μg/kg/h dexmedetomidine are near clinical dosages of 0.3 μg/kg/h and 0.7 μg/kg/h, respectively, both which are commonly used in clinical procedures. 29 However, single doses of 1–160 μg/kg have been employed for a variety of brain injuries in several animal experiments.…”

The effect of dexmedetomidine against oxidative and tubular damage induced by renal ischemia reperfusion in rats

“…In the same study, it has been reported that SOD, CAT and GSH peroxidase (GSH-Px), enzyme activation have been increased. 17 Sugita et al 18 have reported that the dex infusion reduces the renal dysfunction developed by I/R during bilateral renal I/R, and also reduces renal parenchyma interleukin-6 (IL-6), inducible nitric oxide synthase (iNOS) and ICAM-1 mRNA expression. In another study, it has been observed that the dex application reduces kidney caspase 3, plasma ICAM-1 and monocyte chemo attractant protein-1 (MCP-1) levels; and these effects have been inhibited by atipamezole, which is a-2 antagonist.…”